February 19, 2018 — A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC), showing that people with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) taking Xarelto (rivaroxaban) had fewer ischemic strokes compared to those taking aspirin alone. This analysis, which specifically examined patients from COMPASS who experienced a stroke, also found high-risk patients taking Xarelto plus aspirin had the largest reductions in stroke.
CAD and PAD affect 16.5 million and 10 million Americans, respectively, and can serve as red-flag warnings that a more serious cardiovascular (CV) event, like heart attack or stroke, may occur at any time. In fact, each year, approximately 5 percent of people with CAD/PAD will experience a CV event, despite use of preventative medicines.
Xarelto (rivaroxaban) is the only Factor Xa inhibitor to be investigated in CAD and PAD, according to the company. Of note, COMPASS was stopped approximately one year ahead of schedule due to efficacy, and primary results were recently published in The New England Journal of Medicine and presented at the 2017 ESC Congress. In December 2017, Janssen submitted a supplemental New Drug Application (sNDA) to the FDA for two new Xarelto vascular indications based on COMPASS: reducing the risk of major CV events such as CV death, heart attack or stroke in patients with chronic CAD and/or PAD; and for reducing the risk of acute limb ischemia in patients with PAD.
For more information: www.janssen.com